drugset / Trial / NCT02738632

Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

NCT02738632

Phase 3 Completed 300 enrolled IlDong Pharmaceutical Co Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison with Telmisartan/Amlodipine Combination for Essential Hypertension Patients not Controlled by Telmisartan/Amlodipine Combination

Timeline

Start
2015-05
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Hydrochlorothiazide Unknown 25 mg
Background Amlodipine Other / unclassified 5 mg
Background Amlodipine Other / unclassified 10 mg
Background Telmisartan Other / unclassified 40 mg
Background Telmisartan Other / unclassified 80 mg